Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immune and inflammatory diseases. Vera's mission is to develop and commercialize revolutionary new therapies to improve patients' lives. Vera's lead program is atacicept, a fusion protein that acts as a dual inhibitor of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand, currently in development for IgA nephropathy (IgAN), also known as Berger's disease. In the long term, the company is building a pipeline of clinical-stage molecules with the potential to significantly improve people’s lives.